Popular terms

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Receptor patents



      

This page is updated frequently with new Receptor-related patent applications.




Date/App# patent app List of recent Receptor-related patents
07/21/16
20160209773 
 Image processing apparatus, image processing method, and storage medium patent thumbnailnew patent Image processing apparatus, image processing method, and storage medium
An image processing apparatus that generates a halftone image to be used in a case where an image is formed on a printing medium by exposing a photoreceptor by intensity modulation of a light beam, having a multivalued dither processing unit configured to generate n-nary (n≧3) image from an input image by a dither method, a determination unit configured to determine whether a difference in pixel value between pixels adjacent to each other in an exposure scanning direction exceeds a predetermined limit value for each pixel of the n-nary image generated by the multivalued dither processing unit, and a correction unit configured to correct the pixel values of the adjacent pixels whose difference in pixel value has been determined to exceed the predetermined limit value so that the difference does not exceed the limit value.. .
Canon Kabushiki Kaisha


07/21/16
20160209430 
 Methods patent thumbnailnew patent Methods
The present invention relates to a method of identifying a compound that binds to or modulates the activity of one or more polypeptides encoding one or more receptors that are involved in the detection and perception of fatty acids.. .
Mars Incorporated


07/21/16
20160209429 
 Composite compound comprising upconverting nanoparticle and specific receptor patent thumbnailnew patent Composite compound comprising upconverting nanoparticle and specific receptor
Disclosed is a platform detecting glycated hemoglobin as an indicator for diabetes in the blood based on upconverting nanoparticles excited by near-infrared light and luminescence resonance energy transfer.. .
Gwangju Institute Of Science And Technology


07/21/16
20160209426 
 Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists patent thumbnailnew patent Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
Methods of assessing or monitoring the effect, efficacy, responsiveness to treatment, and/or determining a dose or dosing regimen of therapeutic agents, such as integrin beta7 antagonists, for the treatment of gastrointestinal inflammatory disorders are provided. In certain aspects, methods of using integrin beta7 subunit-containing receptor occupancy by the integrin beta7 antagonist on colonic lymphocytes as an indicator (“biomarker”) of the effect, efficacy, or responsiveness to treatment, and/or as a means to determine dosing or dosing regimens of therapeutic agents such as beta7 integrin antagonists for the treatment of gastrointestinal inflammatory disorders are provided.
Genentech, Inc.


07/21/16
20160209424 
 Kit for diagnosis, prognosis, and monitoring the immune status, of patients with chronic inflammatory diseases patent thumbnailnew patent Kit for diagnosis, prognosis, and monitoring the immune status, of patients with chronic inflammatory diseases
Provided is a method and a kit for testing the immune status of patients with chronic inflammatory diseases by measuring the tcr zeta chain (c247) expression levels, and in particular a method and a kit for testing the selective downregulation of tcr zeta chain expression in t cells, nk cells, or nkt cells of such patients. Zeta chain expression is measured using antibodies directed against the intracellular zeta chain region, and these levels are compared with the expression levels of other t cell receptor subunits and nk cell markers.
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd.


07/21/16
20160209420 
 Food allergen detection methods and systems using molecularly imprinted polymers patent thumbnailnew patent Food allergen detection methods and systems using molecularly imprinted polymers
Methods and devices for the detection of food allergens using molecularly imprinted polymers that are imprinted for a target food allergen. A molecularly imprinted polymer may be imprinted using surface imprinting or other procedures.
Allergy Amulet, Inc.


07/21/16
20160209411 
 Compositions and methods for evaluating viral receptor/co-receptor usage and inhibitors of virus entry using recombinant virus assays patent thumbnailnew patent Compositions and methods for evaluating viral receptor/co-receptor usage and inhibitors of virus entry using recombinant virus assays
Provided are methods for identifying whether a compound inhibits entry of a virus into a cell. The method may include obtaining nucleic acid encoding a viral envelope protein from a patient infected by the virus and co-transfecting it into a first cell along with a viral expression vector which lacks a nucleic acid encoding the envelope protein.
Monogram Biosciences, Inc.


07/21/16
20160209367 
 Apparatus made by combining a quartz tuning fork and a microfluidic channel for low dose detection of specific specimens in a liquid or gas media patent thumbnailnew patent Apparatus made by combining a quartz tuning fork and a microfluidic channel for low dose detection of specific specimens in a liquid or gas media
Embodiments of present invention provide apparatus that can measure very low dose of a specific specimen (such as biomarkers, protein) in a liquid or gas media. The apparatus is made of a microfluidic channel in combination by a tuning fork.

07/21/16
20160208216 
 Methods of cell culture for adoptive cell therapy patent thumbnailnew patent Methods of cell culture for adoptive cell therapy
Production and use of novel therapeutic cells, called t-vehicles, in the allogeneic adoptive cell therapy setting allows a wide range of therapeutic benefits to accrue with minimal or no risk of gvhd. T-vehicles are created from donor t cells that are altered to contain therapeutic attributes that do not include their native antigen receptors and can deliver therapeutic benefits irrelevant of their native antigen specificity.

07/21/16
20160208215 
 Generation of endocrine progenitor cells from human pluripotent stem cells using small molecules patent thumbnailnew patent Generation of endocrine progenitor cells from human pluripotent stem cells using small molecules
The present invention relates to differentiation of stem cells into a homogeneous endocrine progenitor cell population suitable for further differentiation into pancreatic beta-cells. The present invention provides methods for obtaining ngn3/nkx2.2 double positive endocrine progenitor cells by exposing precursor cells to a tgf-β type i receptor inhibitor, a bmp antagonist, an adenylate cyclase activator and nicotinamide and/or exposing to the precursor cells to a selection of small molecules..
Takara Bio Europe Ab


07/21/16
20160208018 
new patent

Antibodies and chimeric antigen receptors specific for ror1


Provided are ror1 binding molecules, including anti-ror1 antibodies, including antibody fragments such as variable heavy chain (vh) regions, single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (cars). In some embodiments, the antibodies specifically bind to ror1.
Juno Therapeutics, Inc.


07/21/16
20160208017 
new patent

Mutant interleukin-2 polypeptides


The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the α-subunit of the il-2 receptor, for use as immunotherapeutic agents. In addition, the invention relates to immunoconjugates comprising said mutant il-2 polypeptides, polynucleotide molecules encoding the mutant il-2 polypeptides or immunoconjugates, and vectors and host cells comprising such polynucleotide molecules.
Roche Glycart Ag


07/21/16
20160208008 
new patent

Monoclonal antibodies to transferrin and transferrin receptor antigens, and uses thereof


Some embodiments are directed to monoclonal antibodies (mabs) that bind to transferrin (tf) and transferrin receptor 1 (tfrc), hybridoma lines that secrete these antibodies, and the use of these antibodies to detect tf and tfrc antigens. Some other embodiments are directed to methods and uses for detecting cancer and iron deficiency anemia, as well as methods and uses for distinguishing between early and late stage prostate cancer..
Alper Biotech, Llc


07/21/16
20160208006 
new patent

Methods and compositions for increasing n-acetylglucosaminidase activity in the cns


Provided herein are methods and compositions for treating a subject suffering from an enzyme deficiency in the central nervous system (cns). The bifunctional fusion antibody provided herein comprise an antibody to an endogenous blood brain barrier (bbb) receptor and an enzyme deficient in mucopolysaccharidosis iiib (mps-iiib).
Armagen Technologies, Inc.


07/21/16
20160208005 
new patent

Novel anti-human tslp receptor antibody


An anti-human tslp receptor antibody that specifically binds to human tslp receptor and inhibits an action of human tslp through human tslp receptor. A method for preventing or treating asthma by administering the anti-human tslp receptor antibody or an antigen-binding fragment thereof.
Astellas Pharma Inc.


07/21/16
20160208004 
new patent

Il-17ra-il-17rb antagonists and uses thereof


The present invention relates to interleukin-17 ligand and receptor family members and the discovery that il-17 receptor a and il-17 receptor c form a heteromeric receptor complex that is biologically active. Antagonists of the il-17ra-il-17rb heteromeric receptor complex are disclosed, as well as various methods of use..
Amgen Inc.


07/21/16
20160208003 
new patent

Antibodies


The present invention provides antibodies which bind to an epitope in the extracellular domain of human cc chemokine receptor 4 (ccr4) and which are capable of inhibiting the binding of macrophage-derived chemokine (mdc) and/or thymus and activation regulated chemokine (tarc) to ccr4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields..
Affitech Research As


07/21/16
20160208000 
new patent

Immunoreceptor modulation for treating cancer and viral infections


A method of reducing or relieving immune inhibition in a mammal includes the step of at least partly inhibiting or reducing cd96 activity in one or more cells of the mammal to thereby relieve immune inhibition and/or enhance or restore immune surveillance in the mammal. Typically, inhibiting or reducing cd96 activity does not include, or depend upon, killing of cd96-expressing cells in the mammal.
The Council Of The Queensland Institute Of Medical Research


07/21/16
20160207999 
new patent

Anti-human folate receptor beta antibodies and methods of use


Human anti-human folate receptor beta antibodies and antigen-binding fragments thereof are described, as well as methods of using such antibodies and fragments to treat inflammatory disorders or cancers expressing cell surface frβ.. .
The United States Of America, As Represented By The Secretary Department Of Health And Human Servi


07/21/16
20160207994 
new patent

Modulators of il-12 and/or il-23 for the prevention or treatment of alzheimer's disease


The invention provides antibody against p40, il-12 or il-23 for the prevention or treatment of alzheimer's disease. It further provides ligands to the pair of interleukin 12 or 23 and its specific receptor, specifically an antibody, an antibody fragment, an antibody-like-molecule, for the prevention or treatment of alzheimer's disease.
Charite Universitatsmedizin Berlin


07/21/16
20160207989 
new patent

Conditionally active chimeric antigen receptors for modified t-cells


This disclosure relates to a chimeric antigen receptor for binding with a target antigen. The chimeric antigen receptor comprises at least one antigen specific targeting region including a multispecific antibody evolved from a wild-type antibody or a fragment thereof and having at least one of: (a) a decrease in activity in the assay at the normal physiological condition compared to the wild-type antibody or the fragment thereof, and (b) an increase in activity in the assay under the aberrant condition compared to the wild-type antibody or the fragment thereof.
Bioatla, Llc


07/21/16
20160207976 
new patent

Recombinant platelet collagen receptor glycoprotein vi and its pharmaceutical use


The invention relates to glycoprotein vi (gpvi), its isolation, purification, and methods for recombinant production. Especially, the invention relates to the use of gpvi, preferably recombinant gpvi, in the treatment of disorders and pathological events correlated directly or indirectly to blood coagulation disorders such as thrombotic and cardiovascular diseases.
Sanofi-aventis Deutschland Gmbh


07/21/16
20160207973 
new patent

Designer osteogenic proteins


The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer bmps and have altered affinity for a cognate bmp receptor.

07/21/16
20160207972 
new patent

Recombinant proteins and their therapeutic uses


A recombinant protein expressing one or more human growth factors, tumor antigens, and/or receptors or epitopes thereof on or within an immunogenic expression creating a recombinant protein in which one or more epitopes are presented on the surface of the sequence in their natural configuration. The growth factor, tumor antigen, and/or receptor, sequence(s) may be expressed within the encoding sequence at appropriate internal positions or at the termini as single expressions or as two or more tandem repeats..
Bioven 3 Limited


07/21/16
20160207953 
new patent

Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of asgpr


Compounds of formula (a) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (asgpr) targeting agents.. .
Pfizer Inc.


07/21/16
20160207935 
new patent

Substituted thieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4


In one aspect, the invention relates to substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor m4 (machr m4); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
Vanderbilt University


07/21/16
20160207930 
new patent

Novel neurokinin 1 receptor antagonist compounds ii


The invention relates novel nk1 receptor antagonists represented in formula a, wherein r1 and r2 independently are selected from the group consisting of (c1-4)alkyl, (c1-4)haloalkyl, (c1-4)alkoxy, cd3 or halogen; r3 is selected from the group consisting of hydrogen, (c1-4)alkyl, (c1-4)haloalkyl and (c1-4)hydroxyalkyl; r4 is selected from the group consisting of phenyl, 5-membered heteroaryl and 6-membered heteroaryl; r5 and r6 are independently selected from the group consisting of hydrogen, (c1-4)alkyl, (c1-4) hydroxyalkyl and (c1-4)haloalkyl and x and y are independently selected from the group consisting of ch and n. The invention furthermore relates to intermediates for the preparation of said compounds, to their use in therapy, and to pharmaceutical compositions comprising said compounds..
Leo Pharma A/s


07/21/16
20160207921 
new patent

Ergoline compounds and uses thereof


Provided herein are ergoline compounds and pharmaceutical compositions thereof. In some embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and pharmaceutical compositions disclosed herein.
Xoc Pharmaceuticals, Inc.


07/21/16
20160207920 
new patent

Isoergoline compounds and uses thereof


Provided herein are isoergoline compounds and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and pharmaceutical compositions disclosed herein.
Xoc Pharmaceuticals, Inc.


07/21/16
20160207916 
new patent

Naphthylurea derivatives and medical applications thereof


The present invention relates to naphthylurea derivatives. Such substances can significantly inhibit vegfr2 and pdgfr-β receptor tyrosine kinase phosphorylation at nanomolar concentration levels.
Radiant Pharma & Tech. Co., Ltd.


07/21/16
20160207905 
new patent

Substituted pyrimidine compounds, compositions and medicinal applications thereof


The present disclosure relates to pyrimidine compounds of formula (i), their stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, solvates, and hydrates thereof. The present disclosure also relates to process of preparation of these pyrimidine compounds, and to pharmaceutical compositions containing them.
Jubilant Biosys Limited


07/21/16
20160207890 
new patent

Ethynyl derivatives


It has been surprisingly been found that the compounds of general formula i are positive allosteric modulators (pams) of metabotropic glutamate receptor 4 (mglur4), useful for the treatment of parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.. .
Hoffmann-la Roche Inc.


07/21/16
20160207889 
new patent

Apelin receptor (apj) agonists and uses thereof


This disclosure is directed to agonists of the apelin receptor (apj) and uses of such agonists.. .
Research Triangle Institute


07/21/16
20160207887 
new patent

Antidiabetic tricyclic compounds


Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslip idemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.


07/21/16
20160207880 
new patent

Amide derivatives as lysophosphatidic acid receptor antagonists


Wherein r1, x, m, r2, y, r3, z, n, r4, a and b are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.. .

07/21/16
20160206898 
new patent

Method and determining circadian input


A method and apparatus for determining the circadian input of a light source includes selecting a circadian input to be measured based on an action spectrum corresponding to a wavelength sensitivity of photoreceptors for a circadian regulation system, where the circadian input is configured to stimulate a retinaldehyde photopigment, and for measuring spectral intensity across the action spectrum to determine the circadian input of the light source.. .
Progressive Lighting And Radiometrics, Llc


07/21/16
20160206763 
new patent

Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same


Provided are compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treatment and diagnosis using such compounds and compositions.. .
Navidea Biopharmaceuticals, Inc.


07/21/16
20160206725 
new patent

Compound and vaccination and immunisation


A method of vaccination or immunisation involving the use of a photosensitizing agent, an antigenic molecule, e.g. A vaccine component, and an agent which enhances the effect of photochemical internalization (pci)-mediated vaccination is disclosed wherein the agent is a ligand for a toll-like receptor (tlr), and irradiation is with light of a wavelength effective to activate the photosensitizing agent.
Pci Biotech As


07/21/16
20160206719 
new patent

Combination of vaccination and inhibition of the pd-1 pathway


The present invention relates to a vaccine/inhibitor combination comprising an rna vaccine comprising at least one rna comprising at least one open reading frame (orf) coding for at least one antigen and a composition comprising at least one pd-1 pathway inhibitor, preferably directed against pd-1 receptor or its ligands pd-l1 and pd-l2. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/inhibitor combination.
Curevac Ag


07/21/16
20160206692 
new patent

Engineered integrin binding peptide compositions


Engineered peptides that bind with high affinity (low equilibrium dissociation constant (kd)) to the cell surface receptors of fibronectin (α5β1) or vitronectin (αvβ3 and αvβ5 integrins) are disclosed as useful as imaging tissue. These peptides are based on a molecular scaffold into which a subsequence containing the rgd integrin-binding motif has been inserted.
The Board Of Trustees Of The Leland Stanford Junior University


07/21/16
20160206690 
new patent

Use of toll-like receptor agonist for treating cancer


The present invention is directed to methods and agents used for treating cancer in toll-like receptor 5-expressing tissues by providing a toll-like receptor agonist such as flagellin. The present invention also relates to protecting the liver from a liver toxicity using a toll-like receptor agonist..
Cleveland Biolabs, Inc.


07/21/16
20160206681 
new patent

Method for treating cognitive dysfunction


The present invention provides compositions and methods for treating cognitive impairment or dysfunction in a subject. In particular, the present invention provides a method for using a composition comprising an angiotensin-(1-7) receptor agonist to treat cognitive dysfunction or impairment that is due to a various clinical conditions including, but not limited to, those associated with increase in inflammation, cytokine production, increases in reactive oxygen species, changes in expression of brain inflammatory related genes and/or in the expression of genes involved in learning and memory within the central nervous system of a subject..
Arizona Board Of Regents For The University Of Arizona


07/21/16
20160206656 
new patent

Methods and compositions for dosing in adoptive cell therapy


Provided are methods for administering multiple doses of cells, such as t cells, to subjects for cell therapy. Also provided are compositions and articles of manufacture for use in the methods.
Juno Therapeutics, Inc.


07/21/16
20160206646 
new patent

Bruton's tyrosine kinase as anti-cancer drug target


receptor protein kinases (rptks) transmit extracellular signals across the plasma membrane to cytosolic proteins, stimulating formation of complexes that regulate key cellular functions. Over half of the known tyrosine kinases are implicated in human cancers and are therefore highly promising drug targets.
The Research Foundation For The State University Of New York


07/21/16
20160206644 
new patent

Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof


This application relates to combination therapies including triciribine compounds and epidermal growth factor receptor inhibitor compounds, particularly erlotinib-like compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.. .
University Of South Florida


07/21/16
20160206631 
new patent

Oxysterols that activate liver x receptor signaling and inhibit hedgehog signaling


This invention relates, e.g., to compositions comprising oxysterol compounds represented by formula i or formula ii, e.g., comprising one or more of oxy 16, oxy 22, oxy30, oxy 31, oxy35, oxy37, oxy43, oxy44, oxy45 or oxy47. The compounds are shown to be hedgehog pathway inhibiting, and to act as agonists for liver x receptor (lxr).
The Regents Of The University Of California


07/21/16
20160206624 
new patent

Medicament for treatment of alzheimer's disease


A medicament for therapeutic and/or preventive treatment of alzheimer's disease, which comprises a combination of a retinoic acid receptor (rar) agonist such as am80 and a retinoid x receptor (rxr) agonist such as hx630.. .
Kemphys Ltd.


07/21/16
20160206613 
new patent

Inhibitors of activin-like receptor kinases


The claimed invention is directed to a method for screening a compound that binds to an allosteric site of alk2, the method comprising screening for a compound that is capable of destabilizing the alk2 protein. A further aspect of the invention is directed to a pharmaceutical composition for the treatment and/or prophylaxis of a disease in a vertebrate, said composition comprising at least one alk receptor kinase inhibitor, and optionally a pharmaceutically acceptable carrier, adjuvant and/or diluent..
The Texas A&m University System


07/21/16
20160206597 
new patent

New use


The present invention relates to methods and pharmaceutical compositions for renal protection in a mammal in need thereof, such as a mammal having a disease manifested by atrial enlargement and/or remodeling or suffering from hypertension or heart failure or being prone to suffering from hypertension and/or heart failure, comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of an angiotensin receptor neprilysin inhibitor (arni) or of a combination of an angiotensin receptor blocker (arb) with a neutral endopeptidase inhibitor (nepi) or with a nepi pro-drug to said mammal.. .

07/21/16
20160206593 
new patent

Pharmaceutical for prophylaxis or treatment of hypertension


A pharmaceutical for the prophylaxis or treatment of hypertension or a disease derived from hypertension. The pharmaceutical is characterized by comprising (i) a specific mineralocorticoid receptor antagonist and (ii) one or more components selected from the following components (a) to (c), for administration simultaneously or separately at a time interval: (a) an angiotensin ii receptor antagonist, (b) a calcium antagonist, and (c) a diuretic..
Daiichi Sankyo Company, Limited


07/21/16
20160206592 
new patent

Method for treating amyotrophic lateral sclerosis by inhibition of cxcr4/cxcl12 signaling


The present invention provides use of an inhibitor of g protein-coupled receptor cxcr4 for treating amyotrophic lateral sclerosis (als), for inhibiting glutamate release in astrocytes, or for increasing remyelinization in motor neurons.. .
Ramot At Tel-aviv University Ltd.


07/14/16
20160202269 

Screening pain suppressors and pharmaceutical composition for prevention or treatment of pain


The present invention provides a screening method for pain suppressors, which method is characterized by using netrin-4 and/or a netrin-4 receptor to select a substance capable of inhibiting downstream signaling from netrin-4. According to the screening method of the present invention, pain suppressors useful as a preventive or therapeutic medicine for pain can be identified.
Osaka University


07/14/16
20160202260 

Biomarkers for prostate cancer


The disclosure provides methods of using biomarkers to improve diagnosis of forms of prostate. The method includes testing a biological sample from an individual for a interleukin-8 (il-8), tumor necrosis factor alpha (tnf-a) and soluble tumor necrosis factor-α receptor 1 (stnfr1), and may further include testing for prostate serum antigen (psa).
Health Research, Inc.


07/14/16
20160201135 

Novel estrogen receptor mutations and uses thereof


Novel mutant esr1 molecules and uses are disclosed.. .
Teva Pharmaceutical Industries, Ltd.


07/14/16
20160201129 

Determination of immune cells and other cells


The present invention generally relates to fluidic droplets, and to techniques for screening or sorting such fluidic droplets. In some embodiments, the fluidic droplets may contain cells such as immune cells, which can be analyzed to determine receptor sequences or other useful properties of the cells.
President And Fellows Of Harvard College


07/14/16
20160201067 

Composition for enhancing transgene expression in eukaryotic cells and enhancing production of a target protein encoded by a transgene


Production of dna vectors with the inserted gene of a target protein and the production of recombinant protein in eukaryotic cell cultures is disclosed. A composition for the intensive production of target protein in eukaryotic cells comprises a dna vector with the inserted gene of a target protein and an agonist of cell receptors belonging to the pattern recognition receptor (prr) family selected from the following agonists: tlr2, or tlr4, or tlr5, or tlr7, or tlr8, or tlr9, or nod1 receptor, or nod2 receptor, used in an optimal ratio.
Silezia Group Pte. Ltd


07/14/16
20160201066 

Cytotoxic t cell response modifiers


The present invention relates to a compound selectively binding to a sensory receptor or selectively altering the expression of a sensory receptor for use in a method for treating or preventing a disease associated with a pathologic cellular cytotoxic t cell (ctl) response. Further, the invention relates to means for detecting a sensory receptor for use in a method for diagnosing cellular resistance against ctl response in a patient.
Ruprecht-karls-universitÄt Heidelberg


07/14/16
20160201060 

Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response


The invention provides immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit tlr-mediated signaling in response to a tlr ligand or tlr agonist.
Idera Pharmaceuticals, Inc.


07/14/16
20160200824 

Anti cd30 chimeric antigen receptor and its use


In a first aspect, the present disclosure relates to genetically modified t-cells having a chimeric antigen receptor for use in adoptive cell therapy for treating cd30+cancer in a subject need thereof. In particular, the present disclosure relates to a t-cell containing a specific chimeric antigen receptor being toxic to cd30+cancer cells while being non-toxic to cd30+non-cancer cells.
Universitaet Zu Koeln


07/14/16
20160200822 

Antibodies which bind type i cannabinoid receptor/angiotensis ii receptor heteromers


Compounds and compositions useful for the treatment of liver diseases and methods of treating liver diseases are disclosed. The compounds of the invention specifically interact with heteromers of cannabinoid receptors as compared to monomers or homodimers.
Icahn School Of Medicine At Mount Sinai


07/14/16
20160200819 

Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer


The invention provides chimeric antigen receptors (cars) comprising an antigen binding domain of human antibody 139, an extracellular hinge domain, a transmembrane domain, and an intracellular domain t cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the cars are disclosed.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv


07/14/16
20160200818 

Methods of treating sporadic inclusion body myositis


The disclosure relates to the treatment of sporadic inclusion body myositis and other muscle wasting disorders with novel regimens, which employ a therapeutically effective amount of a myostatin antagonist, e.g., a myostatin binding molecule, e.g., a myostatin antibody or an actrii receptor binding molecule, an actrii receptor antibody, such as the bimagrumab antibody.. .
Novartis Ag


07/14/16
20160200817 

Methods of identifying anti-inflammatory compounds


A mammalian c-type lectin receptor type is identified which is shown to bind igg antibodies or fc fragments, thus inducing ivig-related reversal of inflammation associated with various immune disorders. The identification of a dc-sign receptor type which interacts with igg to promote a biological response reducing inflammation associated with immune disorders provides for methods of screening and selecting compounds which may be useful in treating various immune disorders by acting to modulate a dc-sign(+) cell to signal a second effector macrophage, causing an increase in expression of the fcγriib receptor and in turn inhibiting a cellular-mediated inflammatory response..
The Rockefeller University


07/14/16
20160200814 

Immunoreceptor modulation for treating cancer and viral infections


A method of reducing or relieving immune inhibition in a mammal includes the step of at least partly inhibiting or reducing cd96 activity in one or more cells of the mammal to thereby relieve immune inhibition and/or enhance or restore immune surveillance in the mammal. Typically, inhibiting or reducing cd96 activity does not include, or depend upon, killing of cd96-expressing cells in the mammal.
The Council Of The Queensland Institute Of Medical Research


07/14/16
20160200808 

Method of treatment


A protocol for pain management includes a pharmaceutical composition and its use in ameliorating the sensation of pain. The protocol includes the use of a ccl17 signaling antagonist alone or in combination with another analgesic compound to treat pain associated with inflammatory conditions.
The University Of Melbourne


07/14/16
20160200793 

Flt4 (vegfr-3) as a target for tumor imaging and anti-tumor therapy


The present invention provide purified flt4 receptor tyrosine kinase polypeptides and fragments thereof, polynucleotides encoding such polypeptides, antibodies that specifically bind such polypeptides, and uses therefor.. .
Vegenics Pty Limited


07/14/16
20160200780 

Muteins with tear lipocalin having affinity to human c-met receptor tyrosine kinase and methods for obtaining the same


The present invention relates to novel muteins derived from human tear lipocalin having affinity to human c-met receptor tyrosin kinase (c-met). The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation.
Pieris Ag


07/14/16
20160200734 

Carboxylic acid compounds in treatment of diabetes mellitus


The invention relates to compounds for increasing qpr40 receptor activity and application thereof. These compounds include of a compound of formula (i), pharmaceutically acceptable salts thereof, solvates thereof, isomers thereof, or produgs of the compounds mentioned above, or the mixture of any form above mentioned.
Fujian Haixi Pharmaceuticals Co., Ltd.


07/14/16
20160200733 

Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4


In one aspect, the invention relates to substituted thieno[2,3-b]pyridine-2-carboxamide analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor m4 (machr m4); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
Vanderbilt University


07/14/16
20160200728 

Imidazole-derived modulators of the glucocorticoid receptor


Novel non-steroidal compounds are provided which are useful in treating diseases or disorders associated with modulation of the glucocorticoid receptor, ap-1, and/or nf-kb activity, including metabolic and inflammatory and immune diseases or disorders, having the structure of formula (i): an enantiomer, diastereomer, or tautomer thereof, or a prodrug ester thereof, or a pharmaceutically-acceptable salt thereof, in which the variables are as defined in the specification.. .
Bristol-myers Squibb Company


07/14/16
20160200725 

Quinolone derivatives as fibroblast growth factor receptor inhibitors


Compounds that are fibroblast growth factor inhibitors (fgfr) and are therefore useful for the treatment of diseases treatable by inhibition of fgfr are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds..
Principia Biopharma, Inc.


07/14/16
20160200719 

Cinnoline derivatives useful as cb-1 receptor inverse agonists


The present invention is directed to cinnoline derivatives pharmaceutical compositions containing them and their use in the treatment of disorders and conditions mediated by the cb-1 receptor; more particularly, use in the treatment of disorders and conditions responsive to inverse agonism of the cb-1 receptor. More particularly, the compounds of the present invention are useful in the treatment of metabolic disorders..
Janssen Pharmaceutica Nv


07/14/16
20160200715 

Preparation and use of 7a-heterocycle substituted- 6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists


And the remaining variables are described herein. The compounds of the invention are effective inhibitors of the par-1 receptor.

07/14/16
20160200713 

Preparation and use of 3-pyridyl substituted- 6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists


The compounds of the invention are effective inhibitors of the par-1 receptor. The inventive compounds may be used for the treatment or prophylaxis of disease states such as asc, secondary prevention of myocardial infarction or stroke, or pad..

07/14/16
20160200689 

Delta opioid receptor agonist compounds


Compositions and methods for treatment of sexual dysfunctions by administering to a subject a pharmaceutical composition comprising a delta opioid receptor agonist in an amount effective to delay the onset of ejaculation in the subject during sexual stimulation.. .
Versi Group, Llc


07/14/16
20160200686 

Benzimidazolyl-methyl urea derivatives as alx receptor agonists


Wherein n, d, e, r1, r2, r3, r4, r6, r7, r8 and r9 are as defined in the description, their preparation and their use as pharmaceutically active compounds.. .

07/14/16
20160200685 

Substituted 1,2,3,4-tetrahydroisoquinoline derivatives for the treatment of hormone-dependent diseases


Provided are compounds of general formula a and a′, wherein x1 and x2 are each c, ch or n; r3 and r4 are each h, optionally substituted c1-c30 saturated or unsaturated chemical group, or together form an optionally substituted c5-c8 cycle; z1; z2 and z3 are each n or ch; v is c═o, c═s or ch2; n is from 1 to 12; w1 and w2 are each h, ch2, o or s; and r1 and r2 are each h, cr1c6 alkyl, c1c6 aryl, c1c12 alkylaryl, optionally substituted phenyl, c1c6 alkoxy, c1c6 thioalkoxy, f, cl, br or i. These compounds inhibit steroid sulfatase (sts), act as selective estrogen receptor modulators (serms), increase alkaline phosphatase (alp) activity, and are useful in the treatment of medical conditions involving hormones such as breast cancer, prostate cancer, endometriosis, osteoporosis, benign prostatic hyperplasia and endometrial cancer..
UniversitÉ Laval


07/14/16
20160199611 

Breathing mask and methods thereof


Embodiments of the present invention relate to a breathing mask for alleviating conditions causing sleep apnea and avoiding onset claustrophobia in a patient often caused by a breathing mask. In one embodiment of the present invention, a breathing mask comprises an overhead gear assembly comprising an overhead receptor and a hose attachment connected to the overhead receptor, and a patient interface coupled to a connector tubing and/or valve of the overhead gear assembly, wherein the hose attachment is positioned outside of a line of sight of a user, when the breathing mask is utilized by the user..

07/14/16
20160199500 

Compositions comprising vitamin b12 and intrinsic factor and methods of use thereof


A system for detecting cancer cells that targets the cubilin receptor for the vitamin b12 binding protein, intrinsic factor. A b12 conjugate and intrinsic factor is injected into the blood of a patient.
Syracuse University


07/14/16
20160199488 

Combination therapy for neoplasia treatment


The present invention relates to an insulin-like growth factor (igf) receptor antagonist for use in the treatment of prostate neoplasia, including benign prostatic hyperplasia (bph), prostate cancer, and particularly crpc, wherein the antagonist is used in combination with an androgen receptor antagonist. An embodiment of the invention is where the androgen receptor antagonist is enzalutamide..
Boehringer Ingelheim International Gmbh


07/14/16
20160199479 

T cell receptors


The present invention relates to t cell receptors (tcrs) which bind the hla-a2 restricted clgglltmv peptide (seq id no: 1) derived from the lmp2a protein from epstein barr virus (eby). Tcrs of the invention comprise a tcr alpha chain variable domain and/or a tcr beta variable domain.
Immunocore Limited


07/14/16
20160199458 

Methods of promoting fat loss comprising administering an alk7 inhibitor


The invention relates to alk7 soluble receptors and their uses as antagonists of the function of certain ligands such as gdf-8 (myostatin) and gdf-11. The alk7 soluble receptor of the invention is useful as antagonists of gdf-8 and gdf-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases.
Acceleron Pharma Inc.


07/14/16
20160199451 

Composition for treating hyperlipidemia comprising oxyntomodulin derivative


The present invention relates to a composition for preventing or treating hyperlipidemia, fatty liver disease or arteriosclerosis, comprising an oxyntomodulin derivative as an active ingredient. The oxyntomodulin derivative has a high ability to activate glp-1 receptor and glucagon receptor compared to native oxyntomodulin and has the effects of reducing the blood total cholesterol, low-density cholesterol and triglyceride levels that were increased by high-fat diet, and increasing high-density cholesterol levels and the high-density cholesterol/low-density cholesterol ratio.
Hanmi Pharm. Co., Ltd.


07/14/16
20160199442 

Anti- p2x7 peptides and epitopes


The invention relates to the identification of a novel epitope on non-function p2x7 receptors which are implicated in cancer. The epitope includes a region from two adjacent monomers within the three subunit receptor.
Biosceptre (aust) Pty Ltd


07/14/16
20160199438 

Gip and glp-1 co-agonist compounds


The present invention relates to dual incretin peptide mimetic compounds that agonize receptors for both human glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide-1 (glp-1), and may be useful for treating type 2 diabetes mellitus (t2d).. .
Eli Lilly And Company


07/14/16
20160199364 

Seizure treatment compositions and methods


A composition, a method for administering an anti-seizure composition, and a method for treating a seizure are described. In an implementation, a composition comprises a peroxisome proliferator activated receptor gamma (pparγ) antagonist that is administered to an individual, where the individual has been administered a ketogenic diet.
Creighton University


07/14/16
20160199356 

Cognition enhancing compounds and compositions, methods of making, and methods of treating


The invention relates generally to muscarinic agonists, which are useful for stimulating muscarine receptors, and treating cognitive disorders. Included among the muscarinic agonists disclosed herein are oxadiazole derivatives, compositions, and preparations thereof.
Neurosolis, Inc.


07/14/16
20160199352 

Pyrazoloanthrone and derivatives thereof for treatment of cancers expressing missrii


The present invention relates to pyrazoloanthrones or functional derivatives or functional analogues thereof to activate mis receptor-mediated downstream effects in a cell. In particular, the present invention relates to method to prevent and treat cancer that expresses mis receptor type ii (misrii) by administering to a subject at least one pyrazoloanthrone or a functional derivative or a functional analogue thereof.
The General Hospital Corporation


07/14/16
20160199320 

Ophthalmic treatments


Aqueous compositions suitable for topical administration to the human or animal eye contain at least one water-soluble polymeric ophthalmic lubricant, such as hyaluronate, carbomer gel or hypromellose, together with a water-soluble analgesic. The analgesic may be an opiod, particularly an opioid having an affinity for 5-ht receptors, such as tramadol.
Optosolve Research & Development Limited


07/14/16
20160199042 

Apparatus for drawing of a bodily fluid and method therefor


A sample holder that enables mid-infrared spectroscopy of a test sample using mid-infrared light is disclosed. The sample holder includes an inlet port and a sample chamber that comprises a sample region and a capillary channel that fluidically couples the inlet port and the sample region.





Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Receptor for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Receptor with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.5646

4678

0 - 1 - 102